文献速递贫血与红细胞疾病血栓与止血

白细胞介素-1受体拮抗可改善镰状细胞病小鼠模型的贫血并与体外血小板介导的红细胞镰变减少相关

Interleukin-1 receptor antagonism leads to improved anaemia in a murine model of sickle cell disease and is associated with reduced ex vivo platelet-mediated erythrocyte sickling.
PubMed 文献 · Br J Haematol · 2021-11-16

本研究在镰状细胞病小鼠模型中探讨白介素-1受体(IL-1R)拮抗剂阿那白滞素对贫血的影响。治疗2周内溶血标志物较溶媒组降低;4周后红细胞数、血红蛋白和血细胞比容升高,网织红细胞减少,体外红细胞镰变易感性降低且对IL-1β诱导的镰变抵抗。IL-1β刺激的血小板上清可促进红细胞镰变,该效应可被TGF-β中和抗体、NADPH氧化酶抑制和超氧化物清除剂抑制,但可被重组TGF-β复制。

要点

  • 阿那白滞素治疗4周后镰状细胞病小鼠红细胞数、血红蛋白和血细胞比容升高,网织红细胞减少。
  • 阿那白滞素治疗小鼠血液体外镰变易感性降低,且对IL-1β诱导的镰变抵抗。
  • IL-1β刺激的血小板上清通过TGF-β诱导ROS生成经红细胞NADPH氧化酶促进镰变。

核心结论

  • 药理学IL-1R拮抗可改善镰状细胞病小鼠模型的贫血。
  • IL-1β刺激血小板可促进红细胞镰变,该效应可能由血小板来源TGF-β诱导的活性氧生成经红细胞NADPH氧化酶介导。

研究设计与样本

  • 本研究为在镰状细胞病小鼠模型中开展的实验研究。

主要发现

  • 治疗2周内,阿那白滞素治疗小鼠较溶媒治疗小鼠溶血标志物降低。
  • 阿那白滞素治疗4周后,小鼠红细胞数、血红蛋白和血细胞比容升高,网织红细胞减少。
  • 阿那白滞素治疗小鼠血液体外红细胞镰变易感性降低,且对IL-1β诱导的镰变抵抗。
  • IL-1β刺激的血小板上清可促进红细胞镰变,而IL-1R-/-小鼠血小板上清无此效应。
  • IL-1β刺激血小板上清的镰变效应可被TGF-β中和抗体、NADPH氧化酶抑制和超氧化物清除剂抑制,但可被重组TGF-β复制。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Sickle cell disease (SCD) is associated with haemolytic anaemia and secondary activation of leucocytes and platelets, which in turn may further exacerbate haemolysis. As cytokine signalling pathways may participate in this cycle, the present study investigated whether pharmacological blockade of the interleukin-1 receptor (IL-1R) would mitigate anaemia in a murine model of SCD. Within 2 weeks of treatment, reduced markers of haemolysis were observed in anakinra-treated mice compared to vehicle-treated mice. After 4 weeks of anakinra treatment, mice showed increased numbers of erythrocytes, haemoglobin, and haematocrit, along with reduced reticulocytes. Blood from anakinra-treated mice was less susceptible to ex vivo erythrocyte sickling and was resistant to exogenous IL-1β-mediated sickling. Supernatant generated from IL-1β-treated platelets was sufficient to promote erythrocyte sickling, an effect not observed with platelet supernatant generated from IL-1R-/- mice. The sickling effect of IL-1β-treated platelet supernatant was inhibited by a transforming growth factor-β (TGF-β) neutralising antibody, nicotinamide adenine dinucleotide phosphate (NADPH) oxidase inhibition, and superoxide scavengers, but replicated by recombinant TGF-β. In conclusion, pharmacological IL-1R antagonism leads to improved anaemia in a murine SCD model. IL-1β stimulation of platelets promotes erythrocyte sickling. This effect may be mediated by platelet-derived TGF-β-induced reactive oxygen species generation though erythrocyte NADPH oxidase.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Venugopal J, Wang J, Guo C, et al. Interleukin-1 receptor antagonism leads to improved anaemia in a murine model of sickle cell disease and is associated with reduced ex vivo platelet-mediated erythrocyte sickling. Br J Haematol. 2021. PMID: 34786709. doi:10.1111/bjh.17941

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。